Application note: Reliable MSC expansion and differentiation using animal-free cell culture conditions
Pluripotent stem cells
Webinar: Ensuring compliance with animal-free raw materials in CGT
Webinar details November 20, 2025 The production of cell and gene therapies requires strict adherence to regulatory standards that ensure patient safety and product consistency. However, sourcing high-performing, animal-free raw materials that meet these standards remains a major challenge for many manufacturers. In this webinar, we will share validated solutions using Recombinant Insulin and Trypsin […]
Webinar: Ensuring compliance with animal-free raw materials in CGT
Webinar details November 20, 2025 The production of cell and gene therapies requires strict adherence to regulatory standards that ensure patient safety and product consistency. However, sourcing high-performing, animal-free raw materials that meet these standards remains a major challenge for many manufacturers. In this webinar, we will share validated solutions using Recombinant Insulin and Trypsin […]
Insulin in stem cell culture
Why optimizing insulin supplementation is crucial Stem cells represent one of the most powerful tools in modern biomedical science. Their unique ability to both self-renew and differentiate into specialized cell types makes them invaluable for research, disease modeling, and the development of regenerative therapies. Realizing this potential, however, requires more than the cells themselves—it depends […]
Enhancing efficiency and safety in upstream biomanufacturing
Webinar details March 19, 2025 The use of animal-free reagents in the upstream manufacturing of biologic drugs is a common standard in biomanufacturing, essential for enhancing consistency and safety. Insulin has emerged as a key component in cell culture for biomanufacturing, improving a wide array of processes such as monoclonal antibody (mAb) production in CHO […]
Biosimilar development process
Biosimilar medicines represent an important advancement in healthcare, offering greater patient access to biological therapies that might otherwise be cost-prohibitive. The biosimilar development process revolves around a comprehensive comparability assessment between the proposed biosimilar and its reference biological product. The primary goal of the development process isn’t to establish the efficacy and safety of the […]
Advancing biologics manufacturing
Optimize biologics manufacturing with Recombinant Insulin—enhancing cell growth, yield, and process consistency for therapeutic production.
Accelerate the scale-up to clinical phase: Optimizing stem cell culture performance and viral vector titers
Application note: Enhance your iPSC cultures with Recombinant Insulin
Pluripotent stem cells
From lab to patient-infographic
Monoclonal antibodies | Viral vectors for gene therapy | Cell-based vaccinees | Pluripotent stem cells
